lunedì, 7 settembre 2026

Notizie AIOM – anno XVI n. 662

8 Febbraio 2018

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naıve Advanced Pancreatic Neuroendocrine Tumors

This phase II study investigated whether targeting the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway via PI3K, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) inhibition using BEZ235 may be more effective than mTORC1 inhibition with ...
Leggi tutto

8 Febbraio 2018

BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer

Women with an inherited BRCA1 or BRCA2 mutation may have an impaired ability to repair chemotherapy-induced damage as a result of a state of haploinsufficiency and may experience greater treatment-related toxicity. The objective of this study was to compare the hematologic ...
Leggi tutto

8 Febbraio 2018

Web-app

Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore dell’ovaio è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due ...
Leggi tutto